Based on evaluation of the currently available data and the Rapporteurs’ assessment reports, the CPMP considered that the benefit/ risk profile of loratadine and pseudoephedrine containing medicinal products remains unchanged, and therefore adopted an opinion on 20 November 2003 recommending that the Marketing Authorisations for loratadine and pseudoephedrine containing medicinal products should be maintained in accordance with the SPC set out in Annex III of the Opinion. in the indication: “ symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion”.